H. Jack West
55
Abonné
Personal Information
Entreprise/Lieu de travail
Greater Seattle Area, Washington United States
Profession
Founder, President
Secteur d’activité
Medical / Health Care / Pharmaceuticals
Site Web
http://www.cancergrace.org/lung
À propos
Medical Oncologist with a clinical focus and a strong background in lab-based research. My current interest is in clinical practice with a subspecialized focus on thoracic oncology and GU oncology, as well as translational research in these clinical populations. I have run a wide range of clinical trials for my institution, for clinical trials consortia, and at the national level through the cooperative group network (Southwest Oncology Group).
I also am very interested in educational programs for both physicians and the general public and serve as President and CEO of GRACE, the Global Resource for Advancing Cancer Education.
Mots-clés
lung cancer
nsclc
egfr mutation
cancer
afatinib
erlotinib
acquired resistance
oncology
avastin
crizotinib
tarceva
egfr
bevacizumab
non-small cell lung cancer
ceritinib
xalkori
gefitinib
t790m
alk rearrangement
immune checkpoint inhibitor
genomic testing
ramucirumab
azd9291
sclc
maintenance therapy
chemotherapy
local therapy
iressa
targeted therapy
gilotrif
c-met
tivantinib
taxotere
dll3
adjuvant therapy
lmwh
avelumab
taxol
immunotherapy
nedroparin
paclitaxel
small cell lung cancer
antibody-drug conjugate
low molecular weight heparin
rova-t
genomics
next generation sequencing
cancer genetics
personalized medicine
precision medicine
low dose chest ct screening
ldct
nintedinib
ngs
exon 19
co-1686
exon 21
l858r
del 19
bevacizumab/erlotinib
necitumumab
thoracic radiation therapy
co1686
prophylactic cranial irradiation
pemetrexed
zykadia
alimta
multidisciplinary
chemo/radiation
surgery
radiation
locally advanced nsclc
stage iii nsclc
stage 3
locally advanced
stage iv lung cancer
advanced nsclc
cancer progression
response assessment
disease progression
grace
germline mutation
ct screening
somatic mutation
lung cancer risk
side effects
evolution
adaptation
resistance
no evidence of disease
advanced cancer
micrometastases
systemic therapy
metastatic cancer
ned
social media
cancer care
patient groups
engaged patients
e-patients
online patient communities
cetuximab
erbitux
ldk378
alectinib
alk
metmab
tki
egfr inhibitor
bibw-2992
arq-197
molecular oncology
molecular testing
eml4-alk
nonprofit
medicine 2.0
Tout plus
- Présentations
- Documents
- Infographies